STOCK TITAN

Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

Amneal Pharmaceuticals (NYSE: AMRX) announced the FDA's acceptance of its Biologics License Application (BLA) for Bevacizumab, a biosimilar to Avastin, with a standard review goal date in Q2 2022. Developed with mAbxience, Bevacizumab targets metastatic colorectal cancer and had U.S. sales of approximately $2.8 billion in the past year. The biosimilar Alymsys has already been approved in Europe. This milestone supports Amneal's strategy to enhance its biosimilar portfolio, which includes other products like Filgrastim and Pegfilgrastim.

Positive
  • FDA acceptance of the BLA for Bevacizumab marks a significant milestone for Amneal in the biosimilar market.
  • Bevacizumab's potential market, with U.S. annual sales around $2.8 billion, offers substantial revenue prospects.
  • Collaboration with mAbxience supports robust product development, benefiting Amneal's portfolio.
Negative
  • The competitive landscape in the biosimilar sector may impact pricing and market share.
  • Dependence on a limited number of products for revenue could pose risks if any fail to gain market traction.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Bevacizumab, pursuant to Section 351(k) pathway of the Public Health Service Act, and with a standard review goal date in the second quarter of 2022 according to the BsUFA (Biosimilar User Fee Act).

The biosimilar was developed in collaboration with mAbxience, a Spain-based biotechnology company. Bevacizumab is the biosimilar version of Avastin® and when approved will be marketed under the proprietary name AlymsysTM. Alymsys was approved by the European Medicines Agency (EMA) in February 2021. Amneal and mAbxience believe that the data supports the biosimilarity of its AlymsysTM product to Avastin®.

“The FDA’s acceptance of our BLA for Bevacizumab is a significant milestone in our journey to become an important player in biosimilars,” stated Chirag and Chintu Patel, Co-Chief Executive Officers. As previously announced, the Company expects its initial biosimilar portfolio will include Filgrastim (biosimilar for Neupogen®), Pegfilgrastim (biosimilar for Neulasta®) and Bevacizumab (biosimilar for Avastin®).

Bevacizumab is a vascular endothelial growth factor inhibitor. Amneal is seeking approval for Bevacizumab for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment and metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first line Alymsys-containing regimen. Amneal also intends to seek approval for the remainder of the indications from the reference product label as soon as possible, subject to patent and regulatory exclusivities, by the biosimilarity pathway pursuant to Section 351(k).

According to IQVIA™, a leading healthcare data and analytics provider, U.S. annual sales for Bevacizumab for the 12 months ended April 2021 were approximately $2.8 billion.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. For more information, visit www.amneal.com.

Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; the Company’s strategy for growth; product development; regulatory approvals; market position and expenditures. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and similar words are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: the impact of the COVID-19 pandemic; the impact of global economic conditions; our ability to successfully develop, license, acquire and commercialize new products on a timely basis; our ability to obtain exclusive marketing rights for our products; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to manage our growth through acquisitions and otherwise; our dependence on the sales of a limited number of products for a substantial portion of our total revenues; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to FDA product approval requirements; risks related to federal regulation of arrangements between manufacturers of branded and generic products; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; the continuing trend of consolidation of certain customer groups; our reliance on certain licenses to proprietary technologies from time to time; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our dependence on third-party agreements for a portion of our product offerings; our ability to identify and make acquisitions of or investments in complementary businesses and products on advantageous terms; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; the significant amount of resources we expend on research and development; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

FAQ

What is the FDA's role in Amneal Pharmaceuticals' recent announcement regarding Bevacizumab?

The FDA has accepted Amneal's Biologics License Application for Bevacizumab, marking a key step in its approval process.

What is the market potential for Amneal's Bevacizumab biosimilar?

Amneal's Bevacizumab targets a market with U.S. annual sales of approximately $2.8 billion.

When is the expected review completion date for the Bevacizumab BLA?

The standard review goal date for the Bevacizumab BLA is in the second quarter of 2022.

Who collaborated with Amneal Pharmaceuticals in developing Bevacizumab?

Amneal developed Bevacizumab in collaboration with mAbxience, a biotechnology company based in Spain.

What other products are included in Amneal's initial biosimilar portfolio?

In addition to Bevacizumab, Amneal's initial biosimilar portfolio includes Filgrastim and Pegfilgrastim.

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

AMRX Rankings

AMRX Latest News

AMRX Stock Data

2.40B
135.66M
52.19%
46.48%
1.45%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
Bridgewater